Skip to main content
. Author manuscript; available in PMC: 2022 Apr 10.
Published in final edited form as: Cancer Lett. 2021 Jun 12;518:59–71. doi: 10.1016/j.canlet.2021.06.007

Figure 4: Effect of PMN-MDSCs on CTL proliferation and cancer cell death in PD-L1+ PDO/immune cell co-cultures.

Figure 4:

Changes in morphology and Area (μm2) of (A) MSI-H IM95 gastric cancer/immune cell co-cultures, and (B) huFGO/immune cell co-cultures after 48 and 72 hours of in vitro treatment with vehicle in co-cultures with CTLs (condition 1), nivolumab (condition 2) or cabozantinib (condition 3) in co-cultures with CTLs, nivolumab (condition 4) or a combination of nivolumab and cabozantinib (condition 5) in co-cultures with CTLs and MDSCs. (C) CTL proliferation, (E) organoid viability, and (G) PMN-MDSC numbers were quantified by flow cytometry in MSI-H IM95 organoid/immune cell co-cultures. (D) CTL proliferation, (F) organoid viability, and (H) PMN-MDSC numbers were quantified by flow cytometry in hFGO/immune cell co-cultures. *p<0.05 compared to condition 1, n = 4 organoid co-cultures derived from individual patients or experimental replicates for IM95 cells.